Vemurafenib is a competitive small-molecule serine–threonine kinase inhibitor that functions by binding to the ATP-binding domain of mutant BRAF. Vemurafenib was first licensed for the treatment of advanced melanoma (24). Here, BRAF is linked to melanoma.